Form 4: Doximity Director Executes Pre-Planned Stock Sale Following Class B Share Conversion

A Doximity, Inc. director, Timothy S. Cabral, converted 10,000 Class B shares to Class A and subsequently sold them for approximately $50.58 per share, as part of a pre-arranged Rule 10b5-1 trading plan.

Summary

• Timothy S. Cabral, a Director of Doximity, Inc. (DOCS), engaged in a series of transactions on May 23, 2025.
• Mr. Cabral converted 10,000 shares of Class B Common Stock into 10,000 shares of Class A Common Stock.
• Immediately following the conversion, he disposed of 10,000 shares of Class A Common Stock.
• The sale was executed at a weighted-average price of $50.5796 per share, with individual transactions ranging from $50.3100 to $51.1000.
• This transaction was conducted automatically pursuant to a Rule 10b5-1 trading plan adopted by Mr. Cabral on February 13, 2025.
• Following these transactions, Mr. Cabral beneficially owns 6,360 shares of Class A Common Stock directly and 393,500 stock options (right to buy) directly.
• The stock options held by Mr. Cabral were granted on September 2, 2020, and vest in 36 equal monthly installments after that date, contingent on his continuous service.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While an insider sale can be seen negatively, the fact that it was pre-planned via a 10b5-1 plan mitigates concerns about immediate insider sentiment regarding the company's prospects. It's a routine portfolio management event.

Positives

• The transaction was executed under a Rule 10b5-1 trading plan, indicating a pre-scheduled sale rather than a reaction to immediate company performance, which can reduce negative market interpretation.

Negatives

• A director's sale of shares, even if pre-planned, can sometimes be perceived negatively by investors as it reduces insider ownership.

Risks

• The sale of shares by a director, even under a 10b5-1 plan, could be misinterpreted by the market as a lack of confidence, potentially leading to short-term stock price volatility.

Future Outlook

The document does not provide a future outlook for the company's performance or strategic direction, focusing solely on the reported insider transaction.

Industry Context

This Form 4 filing details a routine insider transaction for Doximity, a digital platform for medical professionals. Such transactions are common across all industries, particularly when executives and directors manage their equity holdings through pre-arranged trading plans like Rule 10b5-1, which are designed to avoid accusations of trading on material non-public information.

Stakeholder Impact

• Shareholders: The sale by a director could lead to minor short-term negative sentiment, but the pre-planned nature of the transaction (10b5-1 plan) generally reduces concerns about insider confidence. It represents a small reduction in direct insider ownership.

Key Dates

Recommendation

Keywords

Doximity, DOCS, SEC Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Director Transaction, Class A Common Stock, Class B Common Stock, Equity Conversion